# Application of matrix-assisted laser desorption ionization time-of-flight mass spectrometry in the detection of vancomycin-resistant and-susceptible Enterococcus faecium

**Authors:** Wei He, Xintong Lin, Xueqin Chen, Liangming Zeng, Xuemin Guo

PMC · DOI: 10.3389/fmicb.2025.1603986 · 2025-06-06

## TL;DR

This study uses MALDI-TOF MS to identify specific protein peaks that can distinguish vancomycin-resistant from vancomycin-susceptible Enterococcus faecium in a regional setting.

## Contribution

The study identifies region-specific MALDI-TOF MS peaks for rapid differentiation of VREfm and VSEfm.

## Key findings

- Stable characteristic peaks for VSEfm and VREfm were identified in the Meizhou region.
- Discriminative efficacy of these peaks was validated using ROC curve analysis.
- The method shows regional specificity and potential for clinical application.

## Abstract

In recent years, the escalating prevalence of Vancomycin-resistant Enterococcus faecium (VREfm) has emerged as a formidable challenge to global healthcare systems. While Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) has become an indispensable tool for bacterial identification, its potential for rapid discrimination between Vancomycin-susceptible Enterococcus faecium (VSEfm) and VREfm through characteristic peak analysis remains an area of active investigation.

In this study, we conducted literature search through databases to summarize the distribution of regionally prevalent VSEfm/ VREfm characteristic peaks, and further collected mass spectrometry data from Meizhou People’s Hospital (Guangdong, China) from 2021 to 2024 to explore stable characteristic peaks for both VSEfm and VREfm.

Through MALDI-TOF MS analysis, we identified stable characteristic peaks for both VSEfm (m/z 3299.95 ± 3.99 and m/z 6605.13 ± 7.28) and VREfm (m/z 3313.01 ± 2.76 and m/z 6631.03 ± 4.38) in the Meizhou region, with their discriminative efficacy validated by ROC curve analysis.

Our findings not only demonstrate the regional specificity of these characteristic peaks but also establish a robust methodological framework for rapid VSEfm/VREfm differentiation. This advancement holds significant promise for guiding clinical decision-making and controlling VREfm dissemination. Nevertheless, we acknowledge the necessity for ongoing technological refinement to enhance the accuracy and broader applicability of this approach in diverse clinical settings.

## Linked entities

- **Chemicals:** Vancomycin (PubChem CID 14969)
- **Species:** Enterococcus faecium (taxon 1352)

## Full-text entities

- **Chemicals:** Vancomycin (MESH:D014640)
- **Species:** Enterococcus faecium (species) [taxon 1352]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12179124/full.md

---
Source: https://tomesphere.com/paper/PMC12179124